TDCS for Auditory Hallucinations in Schizophrenia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01898299|
Recruitment Status : Recruiting
First Posted : July 12, 2013
Last Update Posted : September 15, 2017
|Condition or disease||Intervention/treatment|
|Schizophrenia||Device: transcranial Direct Current Stimulation (tDCS) Device: Sham tDCS|
90 patients with persistent auditory verbal hallucinations will be recruited to this study. Each individual will participate in behavioral assessments lasting up to 3 hours each and will then be randomized to receive a series of active vs. sham tDCS treatments. For active treatment, patients will have the inhibitory (cathodal) tDCS electrode placed over left auditory cortex relative to an anodal placed over frontal cortex on the right side. tDCS treatments will take place for 20 min per day for 5 consecutive days. For sham, procedures will be similar except that sham (inactive) tDCS treatment will be used. Assessment batteries will then be repeated following completion of treatment and at 1 and 3 mo following treatment. In addition, patients will be offered the possibility to participate in a concurrent magnetic resonance imaging (MRI) study aimed at evaluating the effects of tDCS on activation of auditory cortex during an auditory discrimination task as well as on other imaging parameters related to resting brain activity and metabolism. Patients who agree to participate in this MRI study will be scanned before and after active or sham tDCS. In addition, 5-15 schizophrenia patients will complete a week of High-density, e.g., "high-definition" tDCS (HD-tDCS) open label.
In addition to hallucinating patients, we will recruit up to 20 healthy controls and 20 non-hallucinating patients, who will have similar assessments to the patients, but will not receive tDCS.
Overall, the investigators hypothesize that tDCS treatment will lead to reduction in hallucinations, improvement in auditory function, and change in EEG and MRI measurements so that patients more closely resemble healthy volunteers and non-hallucinating patients.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||tDCS for Auditory Hallucinations in Schizophrenia|
|Study Start Date :||May 2013|
|Estimated Primary Completion Date :||March 2018|
|Estimated Study Completion Date :||March 2018|
Experimental: Transcranial Direct Current Stimulation
Transcranial Direct Current Stimulation (tDCS) treatments will take place for 20 minutes per day for 5 consecutive days
Device: transcranial Direct Current Stimulation (tDCS)
A neurostimulation technique that passes an extremely weak electric current through the brain.
Other Name: BrainStim SYS
Sham Comparator: Sham tDCS
Sham tDCS(inactive)treatment (transcranial Direct Current Stimulation) will take place for 20 minutes per day for 5 consecutive days.
Device: Sham tDCS
Sham (inactive) tDCS treatment
- Severity of refractory auditory hallucinations [ Time Frame: Change from baseline in Auditory Hallucination Rating Scale after 5 day treatment ]Auditory hallucinations as determined by Auditory Hallucinations Rating Scale (AHRS)
- Severity of negative schizophrenia symptoms [ Time Frame: Change from baseline in Positive and Negative Symptom Scale after 5 day treatment ]Negative schizophrenia symptoms will be measures using the Positive and Negative Symptom Scale (PANSS)
- Auditory function [ Time Frame: Comparing baseline to after 5 days of treatment ]Optional outcome: Increased amplitude of the auditory steady-state response (ASSR) and N1 auditory event-related potential (ERP) component as well as increased corollary discharge modulation of the N1 auditory ERP produced when patients produce versus listen to speech and auditory word recognition task
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01898299
|Contact: Daniel C Javitt, MDemail@example.com|
|United States, New York|
|New York State Psychiatric Institute||Recruiting|
|New York, New York, United States, 10032|
|Contact: Joshua T Kantrowitz, MD 646-774-6738 firstname.lastname@example.org|
|Nathan Kline Institute||Recruiting|
|Orangeburg, New York, United States, 10962|
|Principal Investigator:||Daniel C Javitt, MD||Nathan Kline Institute, New York State Psychiatric Institute|